Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (DOSE-HEP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01078311
Verified February 2010 by South West Sydney Local Health District. Recruitment status was: Recruiting
Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with advanced HCC who are to commence Sorafenib
ECOG ≤ 2
Histologically or cytologically diagnosed hepatocellular carcinoma, or diagnosis on at least one cross-sectional imaging with the characteristic appearance of HCC (i.e. liver lesion with arterial enhancement and portal venous washout)
Decision to treat with single agent sorafenib at 400mg bid (dose reductions or interruptions are permitted if side effects occur during treatment)
No prior systemic chemotherapy or targeted therapy
Child-Pugh liver function class A or B
At least one untreated target lesion that can be measured in one dimension according to RECIST
Adequate organ functions
Prior systemic chemotherapy or molecularly targeted therapy
Concurrent active malignancy
Concomitant strong CYP3A4 induced or inhibitor at a therapeutic dose (see section 6.4.1)
Medical or psychiatric conditions that compromise the patient's ability to give informed consent
Hypertension that cannot be controlled by medications (> 150/100 mmHg despite optimal medical therapy)
History of, or known brain metastases (skull metastases allowed), carcinomatous meningitis, or leptomenigeal disease
Major surgery (e.g. open abdominal therapy, pelvic, thoracic, orthopaedic or neurosurgery) within 4 weeks of the date of first dose
Local-regional treatment (i.e. percutaneous and trans-arterial procedures) within 4 weeks. Restaging CT or MRI scan must be repeated at least 4 weeks after local-regional treatment and within 3 weeks before the date of first dose
For patients treated with Yttrium (90Y) radiotherapy, a washout period of 2 months is required.
Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol